Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Shubrook, Jay, Colucci, Randall, Guo, Aili, Schwartz, Frank
Médium: Artigo
Jazyk:Inglês
Vydáno: Libertas Academica 2011
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3411543/
https://ncbi.nlm.nih.gov/pubmed/22879789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMED.S5114
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky